Compare Freeport-McMoRan Inc (FCX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Revvity Inc — how do they compare? Freeport-McMoRan Inc trades at $59.28 (market cap $87.65B), while Revvity Inc trades at $110.96 (market cap $12.42B). The key difference: Freeport-McMoRan Inc is far larger — about 7.1× Revvity Inc's market cap, and Freeport-McMoRan Inc pays the higher dividend (0.98%). Which is the better fit depends on your goals.
| FCX | RVTY | |
|---|---|---|
Market Cap | $87.65B | $12.42B |
Sector | Basic Materials | Technology |
52-Week High | $71.73 | $117.75 |
52-Week Low | $35.34 | $82.26 |
Enterprise Value | $94.31B | $14.91B |
Dividend Yield | 0.98% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freeport-McMoRan (FCX) trades at $61.97, up 3.33% with a bearish technical signal despite three consecutive quarterly earnings beats. The copper miner shows improving fundamentals with revenue growth to $25.92B and net income of $2.20B in 2025, supported by strong copper demand. Analyst consensus remains bullish with a $72.94 price target, though the stock faces technical resistance near $63-64 levels.
FCX presents a compelling value proposition with expanding profit margins and strategic positioning in the copper market, though investors face volatility risks from commodity price fluctuations and ongoing negative cash flow trends. The company's expansion pipeline and dividend payments provide additional shareholder value drivers.
RVTY trades at $110.99, down slightly by 0.2% today, near the analyst consensus price target of $111.43. The stock shows a bullish technical trend with recent earnings beats in Q3 2025, Q4 2025, and Q1 2026. Strong profitability metrics include a gross margin of 54.32% and net income margin of 8.26%. Recent news highlights AI integration advancements and FDA clearances, supporting growth prospects.
The outlook is positive with analyst consensus leaning buy (51.72%) and no sell ratings. Key risks include margin pressure and macroeconomic headwinds affecting cash flow, which turned negative in 2025 and 2026. The upcoming Q2 2026 earnings report on August 4, 2026, will be critical for validating current growth trajectory and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
